# Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"

- Link: https://www.thailand-business-news.com/pr-news/medicilon-presents-revolution-medicines-with-the-excellence-in-client-partnership-award
- Published: 2026-10-30T23:00:00+07:00
- Author: PR Newswire

BOSTON, , Oct. 31, 2026 /PRNewswire/ — Dr. Yang Liu, Director of Medicinal Chemistry
at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon’s
Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon’s Drug Discovery and
Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and
their team welcomed them. The two parties held in-depth discussions on project progress,
data transfer, and strategic priorities for the coming year. During the visit, Medicilon
presented Revolution Medicines with the "Excellence in Client Partnership Award,"
recognizing the substantial clinical value of the company’s pioneering pan-KRAS 
drug discovery and development. The award also honors years of joint effort, mutual
trust, and shared success by both R&D teams, setting an outstanding example of bilateral
collaboration.

[⌊Medicilon presented the "Excellence in Client Partnership Award" to its long-time
collaboration partner Revolution Medicines⌉⌊Medicilon presented the "Excellence 
in Client Partnership Award" to its long-time collaboration partner Revolution Medicines⌉[
Medicilon 
presented the "Excellence in Client Partnership Award" to its long-time collaboration
partner Revolution Medicines

**A Three-Year Partnership Built on a Trusted R&D Model**

Over the past three years, Medicilon’s FTE team has worked closely with Revolution
Medicines to tackle R&D technical challenges, consistently prioritizing client needs
and focusing on the single objective of efficiently delivering high-quality molecules.
This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering
work in advancing KRAS—a target once deemed "undruggable"—and congratulated the 
company on the U.S. FDA’s August 2026 approval of the NDA for Daraxonrasib for metastatic
pancreatic cancer. This milestone offers new hope for pancreatic cancer patients
and delivers significant clinical value. The Excellence in Client Partnership Award
recognizes the trust, dedication, and achievements of both teams over more than 
three years of collaboration, reflecting Medicilon’s confidence in a deeper, long-
term partnership.

**In-Depth Discussions Explore New Collaboration Opportunities**

During the discussions, Dr. Wang outlined Medicilon’s growth and its integrated 
R&D platform spanning target discovery to IND submission. Medicilon’s quality system
meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation.
Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs.
Both parties discussed cross-regional data transfer, project management, future 
collaboration, and ways to enhance cross-border R&D efficiency.

**Laboratory Tour**

Subsequently, Drs. Liu and Pota toured Medicilon’s R&D laboratories, visiting the
chemistry and oligonucleotide labs as well as the API and preclinical research facilities,
gaining firsthand insight into Medicilon’s R&D infrastructure and quality management
system.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award" ](http://www.prnasia.com/story/archive/5085386_CN85386_0?rand=184833)